TNFRSF8 and graft versus host disease: Antibody‒drug coupled BV and programmed cell death protein-1 (PD-1) blockers targeting CD30 showed durable clinical activity in patients with relapsed/refractory 10.13039/100023110HL (r/r) who underwent HSCT, and the case data support that PD-1 blockade in combination with BV promotes the antilymphoma effect of grafts after allo-HSCT but may be associated with GVHD development [75].